Jazz Pharmaceuticals presented a review of clinical data assessing the impact of oxybate on sleep quality, sleep architecture, and measures of disrupted nighttime sleep in narcolepsy as one of six abstracts at the 36th annual Psych Congress.
Oxybate is the active ingredient in Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for narcolepsy and idiopathic hypersomnia.
The review encompassed key data from five clinical studies that evaluated all high-sodium oxybates, fixed-dose, and twice-nightly administrations in both oxybate-experienced patients and those who had not undergone prior treatment. The review found that oxybate improved measures of sleep architecture and disrupted nighttime sleep in narcolepsy patients, independent of dosing regimen or prior oxybate experience.
“These compelling data add to the growing body of literature that looks at the effects of oxybate therapy in terms of sleep quality, sleep architecture, and daytime function,” says Richard K. Bogan, MD, FCCP, FAASM, associate clinical professor at the University of South Carolina School of Medicine and Medical University of South Carolina, in a release. “The review found that there was no significant difference in the improvement of sleep quality between oxybate dosing schedules. This is an important endpoint, as many patients utilize the twice-nightly dosing to individualize treatment of their sleep disorder.”
Other highlights from Psych Congress included:
- In narcolepsy:
- A subgroup analysis from the phase 3 study of Xywav in adults with narcolepsy, which found that the treatment’s safety and efficacy were similar in those with and without psychiatric comorbidities, including depression and anxiety, and that there were no signals for the occurrence of new psychiatric disorders in either subgroup
- In idiopathic hypersomnia:
- Two posters featuring results from online surveys of US physicians and patients living with idiopathic hypersomnia that provided insights into physicians’ understanding of the disorder as well as the diagnostic journey and quality of life impact for patients
“Idiopathic hypersomnia has a profound impact on those who live with this debilitating sleep disorder,” says Kelvin Tan, MBBCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals, in a release. “Jazz has a longstanding legacy in sleep medicine, and we are proud of our research into new treatment approaches that may benefit patients living with serious sleep conditions such as idiopathic hypersomnia and narcolepsy. We are presenting multiple datasets that show the significant impact that idiopathic hypersomnia has on patient quality of life, which highlights the need for effective treatment options.”
The Psych Congress 2023 presentations are available on-demand through the conference mobile application. Abstracts and posters will also be published on HMP Global’s Psychiatry & Behavioral Health Learning Network 30 to 60 days after the event.